Revelation Biosciences Inc

REVB

Company Profile

  • Business description

    Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body’s innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

  • Contact

    4660 La Jolla Village Drive
    Suite 100
    San DiegoCA92122
    USA

    T: +1 650 800-3717

    https://www.revbiosciences.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    9

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,674.2049.30-0.57%
CAC 407,589.6636.210.48%
DAX 4023,350.55293.171.27%
Dow JONES (US)42,206.8235.160.08%
FTSE 1008,774.6517.15-0.20%
HKSE23,516.7613.72-0.06%
NASDAQ19,447.4198.86-0.51%
Nikkei 22538,252.46150.77-0.39%
NZX 50 Index12,520.0948.96-0.39%
S&P 5005,967.8413.03-0.22%
S&P/ASX 2008,461.3044.20-0.52%
SSE Composite Index3,365.075.170.15%

Market Movers